Browse > Article

The Up-to-date of Anti-Tuberculosis Treatment  

Lew, Woo-Jin (Korean lnstitute of Tuberculosis)
Publication Information
Tuberculosis and Respiratory Diseases / v.60, no.3, 2006 , pp. 270-276 More about this Journal
Keywords
Citations & Related Records
연도 인용수 순위
  • Reference
1 O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med 2001; 163: 1055-58   DOI
2 Telenti A. Genetics of drug resistance in tuberculosis. In: Iseman MD, Huitt GA, eds. Clinics in chest medicine. Philadelphia: WB Saunders, 1997: 55-64]
3 Tuberculosis Research Centre. Shortening short course chemotherapy: A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tub 2002; 49: 27-38
4 Cambau E, Jarlier V. Resistance to quinolones in mycobacteria. Res Microbiol 1996; 147: 52-9   DOI   ScienceOn
5 Koh WJ, Ahn CH, Kim CH, Ahn YM, Lim SY, Seo JY. The therapeutic effect of 6-month inhaled Interferon- gamma treatment in intractible multi-drug resisdtant pulmonary tuberculosis. Tuberc Respir Dis 2001; 51 (suppl, 2): 116
6 Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDA major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci 2000; 97: 13853-8
7 Hans L Rieder. Interventions for tuberculosis control and elimination. IUATLD 2002, 153-69
8 Kim EK, Shim TS, Lee JY, Oh YM, Lim CM, Lee SD, et al. The adjuvant effect of subcutaneous Interferon- gamma in the treatment of refractory multidrug- resistant pulmonary tuberculosis. Tuberc Respir Dis 2004; 57: 226-33   DOI
9 Jane MT, Utaiwan U, Anthomy M, Pasakorn A, Margaret B, Sanit M, et al. Thalidomide treatment reduces TNF-$\alpha$ production and enhances weight gain in patients with pulmonary tuberculosis. Molecular Medicine 1995; 1(4): 384-97   DOI
10 Joia SM, Michael LR, Adrienne RS, J Keith J, Felix AV, Sonya SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-81   DOI   ScienceOn
11 Chapter 13. Vaccination to prevent tuberculosis and immunomodulatory therapy for persons with active disease. In: Iseman MD. A Clinician's guide to tuberculosis. Lippincott Williams & Wilkins, 2000: 417-25
12 American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62   DOI   ScienceOn
13 Lew WJ, Park YK, Kim HJ, Chang CH, Bai GH, Kim SK. The proportion of rifabutin-susceptible strains among rifampicin-resistant isolates and its specific rpoB mutations. Tuberc Respir Dis 2005; 59(3): 257-265   DOI
14 Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-5   DOI   ScienceOn
15 Onyebujoh PC, Levin JB, Fourie PB, et al. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354: 116-9   DOI
16 Michael H Cynamon. Chemotherapeutic agents for Mycobacterial infections. In: Lloyd N Friedman, ed. Tuberculosis: current concepts and treatment, 2nd edition. CRC Press, 2001: 301-32
17 Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small- molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-66   DOI   ScienceOn
18 Giosue S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-$\alpha$in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998; 158: 1156-62   DOI
19 Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44   DOI   ScienceOn
20 Wallis RS, Nsubuga P, Whalen C, Mugerwa RD. Pentoxifylline therapy in HIV-seropositive persons with tuberculosis: a randomized, controlled trial. J Inf Dis 1996; 174: 727-33   DOI   ScienceOn
21 Han SK. The up-to-date of tuberculosis treatment. The annual course for respiratology 2002, Hanyang Medical School
22 T.R. Sterling. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis 2004; 8(12): 1396-1400
23 Park SK, Jun DS, Lee Y H, Lee DH. Treatment of multidrug-resistant pulmonary tuberculosis with Interferon- gamma subcutaneous injection. Tuberc Respir Dis 2003; 55 (suppl, 2): 84
24 Shim TS, Seoul Asan Medical Center (personal communication)
25 Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Therapy 2005: 1-5